# Epidemiological, pharmacogenomic and clinical impact of catechol-O-methyltransferase on cardiovascular disease

> **NIH NIH K01** · BRIGHAM AND WOMEN'S HOSPITAL · 2021 · $51,555

## Abstract

PROJECT SUMMARY / ABSTRACT
Extension of the funding for this K01 award will support completion of a critical career development goal of a
junior investigator in cardiovascular epidemiology and pharmacogenomics, with special emphasis on the role
of catechol-O-methyltransferase (COMT) in cardiovascular disease (CVD) and preventive treatment. The
extension is warranted because of delays resultING from the COVID-19 pandemic. Despite significant strides
in prevention and management, CVD remains a leading cause of death in the United States.
Pharmacogenomics, the study of how an individual’s genome affects their treatment response, has expanded
our understanding of the pathophysiology and treatment of CVD. However, gene-drug interactions have been
difficult to assess in epidemiologic and clinical studies, in part because of the large sample sizes required for
genome-wide association studies of these interactions and lack of strong candidate genes. COMT, which
encodes a key enzyme in degradation of catecholamines including epinephrine, norepinephrine and catechol
estrogen, is a strong candidate gene with plausible physiological links to both CVD and drug metabolism.
Through this K01 we demonstrated COMT genetic effects on CVD risk with aspirin and estrogen replacement
in the Multiethnic Study of Atherosclerosis, supporting our earlier findings in the Women’s Health Study. Given
the widespread use of aspirin for prevention of CVD, it is imperative that we understand the generalizability,
mechanism and impact of the COMT locus itself and drugs that may share common molecular pathways and
networks with it. This translational research proposal addresses these gaps by conducting a clinical trial to
examine effects of native aspirin on platelet function as a function of COMT genotype. As an emerging genetic
locus with pleiotropic CVD and drug interaction effects, COMT is an excellent model system to probe the
multiple molecular pathways and networks involved in cardiovascular function, disease and treatment and thus
guide the development of novel strategies to attenuate CVD risk, and a promising example in which to develop
personal expertise in cardiovascular epidemiology, systems biology, clinical trials, and other key career
development milestones.

## Key facts

- **NIH application ID:** 10438085
- **Project number:** 3K01HL130625-05S1
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Kathryn Tayo Hall
- **Activity code:** K01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $51,555
- **Award type:** 3
- **Project period:** 2016-02-01 → 2021-10-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10438085

## Citation

> US National Institutes of Health, RePORTER application 10438085, Epidemiological, pharmacogenomic and clinical impact of catechol-O-methyltransferase on cardiovascular disease (3K01HL130625-05S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10438085. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*